The Bispecific Antibody Development pipeline reviews the fundamentals of bispecific antibody developability early in the development process that define an efficacious bispecific molecule to avoid late-stage failures. More than 100 bispecific antibodies are in the clinic currently and ensuring their safety and efficacy is paramount. The Developability of Bispecific Antibodies track will showcase how platforms and engineering along with identifying favorable drug-like properties, including half-life, pk/pd, immunogenicity, stability, and manufacturability, can be considered early to optimize chances for success of multi-specific drug candidates. The Safety and Efficacy of Bispecific Antibodies, ADCs and Combination Therapy track will review clinical results and milestones of emerging constructs and identify the key parameters for the success and safety of these novel formats.

January 16-17

Developability of Bispecific Antibodies

January 18-19

Safety and Efficacy of Bispecific Antibodies, ADCs and Combination Therapy

KEYNOTE & FEATURED PRESENTATIONS:

Predicting Antibody Developability at the Discovery Stage
Peter M. Tessier, PhD, Albert M. Mattocks Professor, Pharmaceutical Sciences & Chemical Engineering, University of Michigan

Avidity Engineering for Bispecific and Multispecific Antibodies
Paul Parren, PhD, CSO, Gyes; Professor, Molecular Immunology, Leiden University Medical Center

Tailoring Bispecifics and ADCs Drug Development to Patient and Tumor Features for Safety and Efficacy Optimization: The Clinical Perspective
Elisa Fontana, MD, PhD, Oncologist and Medical Director, Sarah Cannon Research Institute UK

Recent Progress in Antibody-Drug Conjugate Therapy for Cancer
Aditya Bardia, MD, Director, Breast Cancer Research, Harvard Medical School

If you are working in the following areas join the PepTalk community: